Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 14Active not recruiting 11Withdrawn 4Completed 3Terminated 2Not yet recruiting 2Suspended 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 3venetoclax 2fludarabine 2olverembatinib 1ibrutinib 1fludarabine phosphate 1decitabine and cedazuridine drug combination 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Surveys and Questionnaires 1Ropivacaine 1Platelet Transfusion 1Melphalan 1Maintenance 1Magnetic Resonance Spectroscopy 1Leukapheresis 1Lenalidomide 1JNJ-64619178 1JNJ-64264681 1Inosine Monophosphate 1Imatinib Mesylate 1Dexamethasone 1Daunorubicin 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × decitabine and cedazuridine drug combination × Other hematologic neoplasm × Clear all
NCT04093570 2025-10-31

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Taiho Oncology, Inc.

Phase 2 Enrolling by invitation
332 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡